Beactica Therapeutics AB, a precision oncology company headquartered in Stockholm, Sweden, has announced that its TEAD programme has been selected for a late-breaking presentation at the 2024 American Association for Cancer Research (AACR) Annual Meeting. The conference is scheduled to take place on April 5-10, 2024, in San Diego, California.
Dr. Peter Brandt, Head of Chemistry at Beactica Therapeutics, will present a poster entitled “Degraders of TEAD transcription factors based on interface 3 binders” on Sunday, April 7, 2024, at 1:30 PM – 5:00 PM. The presentation will take place at the San Diego Convention Center, Section 52, with an abstract presentation number: LB029. The session title is “Late-Breaking Research: Chemistry.”
The upcoming presentation will showcase new positive results from studies with novel proteolysis-targeting degraders of TEAD based on interface 3-binding ligands currently under development by Beactica. The data will include head-to-head in vitro comparisons with other classes of TEAD modulators in clinical development, such as palmitoylation inhibitors and direct YAP–TEAD protein–protein interaction inhibitors. The discoveries to be presented at the AACR Annual Meeting are the result of collaboration with Beactica’s partners at the National Center for Advancing Translational Sciences (NCATS), one of 27 institutes and centers at the U.S. National Institutes of Health (NIH).
The AACR Annual Meeting is a key event in the cancer research field, attracting over 20,000 scientists, clinicians, advocates, and other attendees. The conference covers integrative cancer science, global impact, and individualized patient care, offering a platform to showcase the latest developments in cancer research and drug discovery.
TEAD (Transcriptional Enhanced Associate Domain) factors are crucial components of the Hippo signaling pathway, which regulates cell proliferation, apoptosis, and stemness. Dysregulation of the Hippo pathway and subsequent activation of TEAD have been linked to various cancers, including squamous cell carcinoma, head and neck cancer, and gastrointestinal cancers.
Beactica Therapeutics AB is dedicated to advancing a pipeline of novel small molecule therapeutics to target genetically defined cancers with significant unmet medical needs. The company aims to deliver value to patients and shareholders by advancing its programmes to clinical proof of concept. For more information about Beactica Therapeutics, please visit their official website.
Media Contact:
Per Källblad
M.Sc. Ph.D.
CEO
Tel: +46 18 56 08 80
For more Beactica Therapeutics news and updates, visit the official company website.
Source link
